Triptorelin
- Generic Name
- Triptorelin
- Brand Names
- Decapeptyl, Trelstar, Triptodur
- Drug Type
- Small Molecule
- Chemical Formula
- C64H82N18O13
- CAS Number
- 57773-63-4
- Unique Ingredient Identifier
- 9081Y98W2V
- Background
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. S...
- Indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
Investigation of Early Hormonotherapy Efficacy of Prostate Cancer
- Conditions
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2006-09-13
- Lead Sponsor
- Kaunas University of Medicine
- Target Recruit Count
- 61
- Registration Number
- NCT00375687
- Locations
- ๐ฑ๐น
Urology dep. of Kaunas University of Medicine, Kaunas, Lithuania
Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
- Conditions
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Gruppo Italiano Mammella (GIM)
- Target Recruit Count
- 280
- Registration Number
- NCT00311636
- Locations
- ๐ฎ๐น
Ospedale Civile, Castelfranco - TV, Italy
๐ฎ๐นIstituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
๐ฎ๐นOspedale Sant Anna, Como, Italy
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 378
- Registration Number
- NCT00104741
- Locations
- ๐ซ๐ท
Centre Hospital Regional Universitaire de Limoges, Limoges, France
๐ซ๐ทCentre Hospitalier Universitaire Henri Mondor, Creteil, France
๐ซ๐ทClinique De Rochebelle, Ales, France
Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer
- First Posted Date
- 2004-09-08
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 49
- Registration Number
- NCT00090844
- Locations
- ๐บ๐ธ
MBCCOP - JHS Hospital of Cook County, Chicago, Illinois, United States
๐บ๐ธMBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States
๐บ๐ธCCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States
Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2003-12-09
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- St. Luke's Hospital, Ireland
- Target Recruit Count
- 276
- Registration Number
- NCT00003734
- Locations
- ๐ฎ๐ช
Cork University Hospital, Cork, Ireland
๐ฎ๐ชLetterkenny Hospital, Donnegal, Ireland
๐ฎ๐ชSt. Vincent's Hospital, Dublin, Ireland
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 2672
- Registration Number
- NCT00066703
- Locations
- ๐บ๐ธ
Elkhart General Hospital, Elkhart, Indiana, United States
๐บ๐ธMemorial Hospital of South Bend, South Bend, Indiana, United States
๐บ๐ธGreenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Premenopausal Endocrine Responsive Chemotherapy Trial
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 29
- Registration Number
- NCT00066807
- Locations
- ๐จ๐ญ
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
๐จ๐ญKantonsspital - St. Gallen, St. Gallen, Switzerland
๐ฎ๐นCentro di Riferimento Oncologico - Aviano, Aviano, Italy
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 3066
- Registration Number
- NCT00066690
- Locations
- ๐บ๐ธ
Charlotte Hungerford Hospital Center for Cancer Care, Torrington, Connecticut, United States
๐บ๐ธUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
๐บ๐ธFinley Hospital, Dubuque, Iowa, United States
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 966
- Registration Number
- NCT00003026
- Locations
- ๐ณ๐ฑ
St. Elisabeth Ziekenhuis, Tilburg, Netherlands
๐ณ๐ฑAcademisch Ziekenhuis Groningen, Groningen, Netherlands
๐ฌ๐งCity General Hospital, Stoke-On-Trent, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.